Compare OMH & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMH | GDTC |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | Singapore | Singapore |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 15.5M |
| IPO Year | 2023 | 2023 |
| Metric | OMH | GDTC |
|---|---|---|
| Price | $1.78 | $1.05 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 38.4K |
| Earning Date | 11-28-2025 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,264,748.00 | $573,193.00 |
| Revenue This Year | $28.40 | $5.37 |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 78.86 | 63.03 |
| 52 Week Low | $0.59 | $0.89 |
| 52 Week High | $4.46 | $3.68 |
| Indicator | OMH | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 87.78 | 26.33 |
| Support Level | $0.80 | $0.89 |
| Resistance Level | $1.83 | $1.39 |
| Average True Range (ATR) | 0.17 | 0.14 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 93.87 | 18.92 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.